Overview

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

Status:
Completed
Trial end date:
2017-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.
Phase:
Phase 4
Details
Lead Sponsor:
LG Life Sciences